Relationship between rehospitalization and future death in patients treated for potentially lethal arrhythmia

被引:14
作者
Hallstrom, AP
Greene, HL
Wilkoff, BL
Zipes, DP
Schron, E
Ledingham, RB
机构
[1] Univ Washington, Seattle, WA 98195 USA
[2] Cleveland Clin Fdn, Cleveland, OH 44195 USA
[3] Indiana Univ, Sch Med, Krannert Inst Cardiol, Indianapolis, IN 46202 USA
[4] NHLBI, NIH, Bethesda, MD 20892 USA
关键词
sudden death; fibrillation; heart failure; risk factors;
D O I
10.1046/j.1540-8167.2001.00990.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: It is generally considered that death is the only appropriate endpoint to evaluate interventions for preventing death; however, this belief may be based on the previous use of inappropriate or inadequate surrogates for death. The aim of this study was to evaluate whether rehospitalization following implementation of an intervention is a reasonable surrogate for death. Methods and Results: The time from discharge following intervention to rehospitalization was evaluated for 997 patients discharged after baseline hospitalization in the Antiarrhythmics Versus Implantable Defibrillators Trial. The relationship between rehospitalization for various reasons and subsequent death was compared in the two treatment arms to assess the adequacy of rehospitalization as a surrogate for death. Included were rehospitalization for: any reason, a cardiac problem, a noncardiac problem, new or worsened congestive heart failure (CHF), an acute coronary syndrome, and a cardiac procedure. For all of the reasons except cardiac procedure, rehospitalization was associated with a substantially increased hazard for subsequent death. Rehospitalization for new or worsened CHF was most closely (that is, temporally) related to subsequent death and was the only reason for rehospitalization, which fully explained the treatment effect of implantable cardiac defibrillators compared with antiarrhythmic drugs on death. Conclusion: Rehospitalization is a significant risk factor for subsequent death. However, only rehospitalization for new or worsened CHF appears to be a potential surrogate for death in the setting of antiarrhythmic interventions.
引用
收藏
页码:990 / 995
页数:6
相关论文
共 16 条
[1]  
[Anonymous], 1989, NEW ENGL J MED, V321, P406
[2]  
Daniels MJ, 1997, STAT MED, V16, P1965, DOI 10.1002/(SICI)1097-0258(19970915)16:17<1965::AID-SIM630>3.3.CO
[3]  
2-D
[4]   Relative effectiveness of the implantable cardioverter-defibrillator and antiarrhythmic drugs in patients with varying degrees of left ventricular dysfunction who have survived malignant ventricular arrhythmias [J].
Domanski, MJ ;
Sakseena, S ;
Epstein, AE ;
Hallstrom, AP ;
Brodsky, MA ;
Kim, S ;
Lancaster, S ;
Schron, E .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1999, 34 (04) :1090-1095
[5]   SURROGATE ENDPOINTS IN CLINICAL-TRIALS - CANCER [J].
ELLENBERG, SS ;
HAMILTON, JM .
STATISTICS IN MEDICINE, 1989, 8 (04) :405-413
[6]  
EPSTEIN AE, 1995, AM J CARDIOL, V75, P470
[7]  
Friedman LM, 1985, FUNDAMENTALS CLIN TR
[9]   SURROGATE ENDPOINTS IN CLINICAL-TRIALS - OPHTHALMOLOGIC DISORDERS [J].
HILLIS, A ;
SEIGEL, D .
STATISTICS IN MEDICINE, 1989, 8 (04) :427-430
[10]  
HUGHES MD, 1995, J ACQ IMMUN DEF SYND, V10, pS1